Drugs / Quinagolide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03749109 | Aug 2019 → Jun 2021 | endometriosis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03692403 | Dec 2018 → Feb 2022 | endometriosis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00665041 | May → Aug 2008 | ovarian hyperstimulation syndrome | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 2 | NCT00329693 | Jun 2006 → Aug 2007 | ovarian hyperstimulation syndrome | Ferring Pharmaceuticals | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04107480 Comparator | Jun 2019 → Mar 2024 | prolactin-producing pituitary gland adenoma | Leiden University Medical Center | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quinagolide | “The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.” PMID 20139430 ↗ Feb 20104“Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide.” NCT04107480 ↗ |
| Known as | Quinagolida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2218861 ↗ |
| Action | Activate | “Dopamine D2 receptor agonist” CHEMBL2218861 ↗ |
| Action | Inhibit | “as quinagolide inhibits the VEGF signaling pathway.” PMID 40188683 ↗ Mar 2025 |
| Modality | Other / unclassified | “non-ergot derived dopamine agonist quinagolide” PMID 20139430 ↗ Feb 2010 |
| Route | Oral | “three oral doses (50, 100, 200 microg/day)” PMID 20139430 ↗ Feb 2010 |
| Target | DRD2 | “Dopamine D2 receptor agonist” CHEMBL2218861 ↗ |